Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 4
2015 7
2016 5
2017 2
2018 3
2019 3
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Association of Sperm-Associated Antigen 5 and Treatment Response in Patients With Estrogen Receptor-Positive Breast Cancer.
Abdel-Fatah TMA, Ball GR, Thangavelu PU, Reid LE, McCart Reed AE, Saunus JM, Duijf PHG, Simpson PT, Lakhani SR, Pongor L, Gyorffy B, Moseley PM, Green AR, Pockley AG, Caldas C, Ellis IO, Chan SYT. Abdel-Fatah TMA, et al. Among authors: moseley pm. JAMA Netw Open. 2020 Jul 1;3(7):e209486. doi: 10.1001/jamanetworkopen.2020.9486. JAMA Netw Open. 2020. PMID: 32633764 Free PMC article.
Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer.
Naidoo K, Wai PT, Maguire SL, Daley F, Haider S, Kriplani D, Campbell J, Mirza H, Grigoriadis A, Tutt A, Moseley PM, Abdel-Fatah TMA, Chan SYT, Madhusudan S, Rhaka EA, Ellis IO, Lord CJ, Yuan Y, Green AR, Natrajan R. Naidoo K, et al. Among authors: moseley pm. Mol Cancer Ther. 2018 Jan;17(1):306-315. doi: 10.1158/1535-7163.MCT-17-0760. Epub 2017 Nov 13. Mol Cancer Ther. 2018. PMID: 29133620 Free PMC article.
SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment.
Abdel-Fatah TMA, Broom RJ, Lu J, Moseley PM, Huang B, Li L, Liu S, Chen L, Ma RZ, Cao W, Wang X, Li Y, Perry JK, Aleskandarany M, Nolan CC, Rakha EA, Lobie PE, Chan SYT, Ellis IO, Hwang LA, Lane DP, Green AR, Liu DX. Abdel-Fatah TMA, et al. Among authors: moseley pm. Br J Cancer. 2019 Apr;120(7):728-745. doi: 10.1038/s41416-019-0405-x. Epub 2019 Feb 28. Br J Cancer. 2019. PMID: 30816325 Free PMC article.
Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers.
Arora A, Abdel-Fatah TM, Agarwal D, Doherty R, Croteau DL, Moseley PM, Hameed K, Green A, Aleskandarany MA, Rakha EA, Patterson K, Ball G, Chan SY, Ellis IO, Bohr VA, Bryant HE, Madhusudan S. Arora A, et al. Among authors: moseley pm. Carcinogenesis. 2016 Jan;37(1):63-71. doi: 10.1093/carcin/bgv163. Epub 2015 Nov 19. Carcinogenesis. 2016. PMID: 26586793 Free PMC article.
High mobility group protein B1 is a predictor of poor survival in ovarian cancer.
Machado LR, Moseley PM, Moss R, Deen S, Nolan C, Spendlove I, Ramage JM, Chan SY, Durrant LG. Machado LR, et al. Among authors: moseley pm. Oncotarget. 2017 Aug 24;8(60):101215-101223. doi: 10.18632/oncotarget.20538. eCollection 2017 Nov 24. Oncotarget. 2017. PMID: 29254158 Free PMC article.
Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells From Patients With Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer.
Foulds GA, Vadakekolathu J, Abdel-Fatah TMA, Nagarajan D, Reeder S, Johnson C, Hood S, Moseley PM, Chan SYT, Pockley AG, Rutella S, McArdle SEB. Foulds GA, et al. Among authors: moseley pm. Front Immunol. 2018 Sep 11;9:2028. doi: 10.3389/fimmu.2018.02028. eCollection 2018. Front Immunol. 2018. PMID: 30254632 Free PMC article. Clinical Trial.
19 results